ConductScience.org, home

Paper36926709

Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity.

Ahmed Z. Neural Regen Res, 2023. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity. Papers, record 36926709. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36926709

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Reviving the use of inhibitors of matrix metalloproteases in spinal cord injury: a case for specificity.
PubMed
Journal
Neural Regen Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.52
iCite
Revised in PubMed
2023-06-03
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ahmed ZZubair

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References73

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119631747Human umbilical cord blood stem cells upregulate matrix metalloproteinase-2 in rats after spinal cord injury.Neurobiol Dis2009https://conductscience.org/library/papers/19631747PubMed
217318226Matrix metalloproteinases and the regulation of tissue remodelling.Nat Rev Mol Cell Biol2007https://conductscience.org/library/papers/17318226PubMed
318264108Distinct roles of matrix metalloproteases in the early- and late-phase development of neuropathic pain.Nat Med2008https://conductscience.org/library/papers/18264108PubMed
421624491Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.Pulm Pharmacol Ther2011https://conductscience.org/library/papers/21624491PubMed
522198278Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential.Nat Med2011https://conductscience.org/library/papers/22198278PubMed
611923444NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors.J Neurosci2002https://conductscience.org/library/papers/11923444PubMed
711567062Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia.J Neurosci2001https://conductscience.org/library/papers/11567062PubMed
822853439Neuroprotective effects of sulforaphane after contusive spinal cord injury.J Neurotrauma2012https://conductscience.org/library/papers/22853439PubMed
918511041Remote activation of microglia and pro-inflammatory cytokines predict the onset and severity of below-level neuropathic pain after spinal cord injury in rats.Exp Neurol2008https://conductscience.org/library/papers/18511041PubMed
1014689443The TIMPs tango with MMPs and more in the central nervous system.J Neurosci Res2004https://conductscience.org/library/papers/14689443PubMed
118958220Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability.J Clin Invest1996https://conductscience.org/library/papers/8958220PubMed
1210998420
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.
J Biol Chem2000https://conductscience.org/library/papers/10998420PubMed
1311095516Metalloproteinase increases in the injured rat spinal cord.Neuroreport2000https://conductscience.org/library/papers/11095516PubMed
1434491542Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis.Pain Ther2021https://conductscience.org/library/papers/34491542PubMed
1527377304Exploratory study to suggest the possibility of MMP-8 and MMP-9 serum levels as early markers for remission after traumatic spinal cord injury.Spinal Cord2017https://conductscience.org/library/papers/27377304PubMed
1612196576Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events.J Neurosci2002https://conductscience.org/library/papers/12196576PubMed
1711687497How matrix metalloproteinases regulate cell behavior.Annu Rev Cell Dev Biol2001https://conductscience.org/library/papers/11687497PubMed
1819712708To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.Biochim Biophys Acta2010https://conductscience.org/library/papers/19712708PubMed
1917217414Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury.J Neurochem2007https://conductscience.org/library/papers/17217414PubMed
2018848143Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection.J Am Coll Cardiol2008https://conductscience.org/library/papers/18848143PubMed

See all 73 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
40822305Localised delivery of interleukin-13 from a PLGA microparticle embedded GelMA hydrogel improves functional and histopathological recovery in a mouse contusion spinal cord injury model.Bioact Mater2025https://conductscience.org/library/papers/40822305PubMed
39470872Mechanisms and Therapeutic Prospects of Microglia-Astrocyte Interactions in Neuropathic Pain Following Spinal Cord Injury.Mol Neurobiol2025https://conductscience.org/library/papers/39470872PubMed
38792314Spinal Cord Injury Management Based on Microglia-Targeting Therapies.J Clin Med2024https://conductscience.org/library/papers/38792314PubMed

Download CSV of cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MMP124321PubTator's text mininghttps://conductscience.org/library/genes/4321NCBI Gene
MMP134322PubTator's text mininghttps://conductscience.org/library/genes/4322NCBI Gene
MMP24313PubTator's text mininghttps://conductscience.org/library/genes/4313NCBI Gene
MMP84317PubTator's text mininghttps://conductscience.org/library/genes/4317NCBI Gene
MMP94318PubTator's text mininghttps://conductscience.org/library/genes/4318NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36926709

GET https://conductscience.org/api/papers/v1/36926709/references?page=2